MedTrace Logo

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2016-11-02

Study results available
· View outcomes & findings →

Summary

The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.

Conditions

Interventions

DRUG

Risperidone

Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study

DRUG

Olanzapine

Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study

DRUG

Quetiapine

Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study

DRUG

Aripiprazole

Switching medication to aripiprazole for schizophrenia for up to 6 months in study

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • T. Scott Stroup, MD, MPH · Columbia University

  • Joseph P. McEvoy, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-10-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423878 on ClinicalTrials.gov